Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
Fulcher GR, Akhtar S, Al-Jaser SJ, Medina J, Mohamed M, Nicodemus NA Jr, Olsen AH, Singh KP, Kok A. Fulcher GR, et al. Among authors: singh kp. Adv Ther. 2023 Jan;40(1):389-390. doi: 10.1007/s12325-022-02349-1. Adv Ther. 2023. PMID: 36315342 Free PMC article. No abstract available.
ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design.
Fulcher GR, Jarlov H, Piltoft JS, Singh KP, Liu L, Mohamed M, Nicodemus NA Jr, Al-Jaser SJ, Kok A. Fulcher GR, et al. Among authors: singh kp. Endocrine. 2021 Dec;74(3):530-537. doi: 10.1007/s12020-021-02887-8. Epub 2021 Oct 12. Endocrine. 2021. PMID: 34637072 Free PMC article.
Correction: ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in realworld settings: rationale and design.
Fulcher GR, Jarlov H, Piltoft JS, Singh KP, Liu L, Mohamed M, Nicodemus NA Jr, Al-Jaser SJ, Kok A. Fulcher GR, et al. Among authors: singh kp. Endocrine. 2022 Mar;75(3):964. doi: 10.1007/s12020-021-02956-y. Endocrine. 2022. PMID: 34919203 Free PMC article. No abstract available.
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
Fulcher GR, Akhtar S, Al-Jaser SJ, Medina J, Mohamed M, Nicodemus NA Jr, Olsen AH, Singh KP, Kok A. Fulcher GR, et al. Among authors: singh kp. Adv Ther. 2022 Aug;39(8):3735-3748. doi: 10.1007/s12325-022-02212-3. Epub 2022 Jun 25. Adv Ther. 2022. PMID: 35752730 Free PMC article. Clinical Trial.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study.
Baruah MP, Aneja P, Pitale S, Bhograj A, Agrawala RK, Aggarwal A, Mahadev PG, Madhavdas DC, Shah S, John M, Pathan MKA, Revanna M, Chandrappa M, Singh KP. Baruah MP, et al. Among authors: singh kp. J Family Med Prim Care. 2024 Sep;13(9):3590-3597. doi: 10.4103/jfmpc.jfmpc_1401_23. Epub 2024 Sep 11. J Family Med Prim Care. 2024. PMID: 39464932 Free PMC article.
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Aravind SR, Singh KP, Mogylnytska L, Zalevskaya AG, Matyjaszek-Matuszek B, Wernicke-Panten K, Nguyên-Pascal ML, Pierre S, Rotthaeuser B, Kramer D, Mukherjee B. Aravind SR, et al. Among authors: singh kp. Diabetes Ther. 2022 Jul;13(7):1299-1310. doi: 10.1007/s13300-022-01279-z. Epub 2022 Jun 1. Diabetes Ther. 2022. PMID: 35650350 Free PMC article.
Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment).
Kesavadev J, Gowda A, Kumar H, Yalamanchi SR, Lodha S, Singh KP, Basu D, Asirvatham A, Shah N, Pathan MK, Revanna M, Mukherjee JJ. Kesavadev J, et al. Among authors: singh kp. Med Sci (Basel). 2021 Dec 21;10(1):1. doi: 10.3390/medsci10010001. Med Sci (Basel). 2021. PMID: 35076540 Free PMC article.
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Aravind SR, Singh KP, Aquitania G, Mogylnytska L, Zalevskaya AG, Matyjaszek-Matuszek B, Wernicke-Panten K, Nguyên-Pascal ML, Pierre S, Rotthaeuser B, Kramer D, Mukherjee B. Aravind SR, et al. Among authors: singh kp. Diabetes Ther. 2022 May;13(5):1053-1071. doi: 10.1007/s13300-022-01255-7. Epub 2022 Apr 14. Diabetes Ther. 2022. PMID: 35420397 Free PMC article.
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
944 results